Investment
Features
FeesSafety
Academy
More
Pluang+

Summit Therapeutics upgraded to Buy after FDA accepts BLA for lung cancer drug ivonescimab.

Analyst Insights
22 Jul 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Summit Therapeutics has been upgraded from 'Hold' to 'Buy' following the FDA's acceptance of its Biologics License Application (BLA) for ivonescimab combined with chemotherapy to treat EGFR-mutant non-small cell lung cancer (NSCLC). The company's Phase 3 HARMONi trial showed improved overall survival data, with risk reduction in death compared to current treatments. Key upcoming events include the FDA decision expected by November 14, 2026, and interim trial data later that year. However, investors should be aware of risks such as cash burn and potential dilution.

More News (SMMT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App